| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3824 |
| Trial ID | NCT06340737 |
| Disease | Follicular Lymphoma | Mantle Cell Lymphoma | Hairy Cell Leukemia | Lymphoplasmacytic Lymphoma | Burkitt Lymphoma | Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Lymphomas |
| Year | 2024 |
| Country | United States |
| Company sponsor | Stanford University |
| Other ID(s) | IRB-73394 |
| Cohort 1 | |||||||||||
|
|||||||||||